99 Anxiety and Depression in Patients With Variable Common Immunodeficiency in the Service of Allergy and Clinical Immunology - Centro Médico Nacional Siglo XXI

Abstract

BackgroundDepression and anxiety disorder are topics of interest, not only to psychiatrists. It comes in a 10 to 20% of cases, with the highest figures in people with chronic diseases. It has been shown that depressed patients have more mortality (not only attributable to suicide) than the general population. Depressive disorders in the community reach a lifetime prevalence of 15%. The average age of onset is situated close to 30 years, being similar in both sexes. The Variable Common Immunodeficiency (ICV) is a disorder characterized by low levels of immunoglobulins (Ig), these patients have an increased susceptibility to infection. The exact cause of low levels of serum Ig is not known and autoimmune diseases is complicated by up to 20%. It has a prevalence estimated at 1 in 25,000, is the most common primary immunodeficiencies, however, the diagnosis is not made until the third and fourth decade of life.ObjectiveTo evaluate the presence of anxiety disorders and depression in patients with ICV.MethodsA cohort study, observational, cross-fifteen patients (11 female and 4 male) with ICV, aged between 17 and 71, diagnosed with ICV. Are individually applied assessment instruments and the preparation of tables and graphs. The data were expressed in absolute figures and percentages.Results1) 13.3% had very severe, 6.6% had severe, 13.3% moderate and 66.6% mild depression. 2) 33.3% moderate-severe anxiety and 66.6% mild.ConclusionsIn this study, most patients are between the second and third decade of life, the moderate-severe anxiety was found in 5 patients and mild in 10 patients, a mild depression 10, a moderate 2, a severe 1 and 2 very severe. This allows to evaluate the ability of the patient with ICV to accept their illness and see the level of infection on the psychological, and offer a multidisciplinary therapy with counseling and/or psychiatric treatment for patients with moderate-severe anxiety and moderate depression to very severe and thus improve their quality of life. These patients have associated autoimmune disorders and family problems.